Table 2.
XR-NTX n = 126 |
Placebo n = 124 |
Rate Ratio (95% CI) |
|
---|---|---|---|
Patients with ≥2 consecutive positive UDT results | 4.8% (6) | 12.9% (16) | 0.37 (0.15–0.91) |
Dropout immediately preceded by a positive UDT result | 3.2% (4) | 16.1% (20) | 0.20 (0.07–0.56) |
Completed the study with no positive or missing UDT results | 31.0% (39) | 20.2% (25) | 1.53 (0.99–2.38) |
UDT = urine drug test; XR-NTX = extended-release naltrexone.